BEXMAB Study Update
Faron Pharmaceuticals Oy (“Faron” or “Company”) Inside Information: Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies BEXMAB Study Update Partial responder becomes complete responder with complete remission of blasts in blood and bone marrow followed by normalization of blood counts Second patient demonstrated a partial response Stable disease observed in the other treated patients Two patients enrolled in second cohort with increased bexmarilimab dose with azacitidine Enrolment initiated